These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 4036802)

  • 1. Third party prescription programs: cost containment issues and strategies.
    Richards JW
    Am Pharm; 1985 Jul; NS25(7):28-35. PubMed ID: 4036802
    [No Abstract]   [Full Text] [Related]  

  • 2. The nature and consequences of policies intended to contain costs in outpatient drug insurance programs.
    Reutzel TJ
    Clin Ther; 1993; 15(4):752-64. PubMed ID: 8221825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimating a reasonable reimbursement for community pharmacies in third-party programs.
    Carroll NV
    Manag Care Interface; 1999 Feb; 12(2):73-6, 79-80. PubMed ID: 10346189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Third-party reimbursement for generic prescription drugs: The prevalence of below-cost reimbursement in an environment of maximum allowable cost-based reimbursement.
    Murry L; Gerleman B; Urick B; Urmie J
    J Am Pharm Assoc (2003); 2018; 58(4):421-425. PubMed ID: 29861152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic impact of cost-containment strategies in third party programmes in the US (part I).
    Reeder CE; Lingle EW; Schulz RM; Mauch RP; Nightengale BS; Pedersen CA; Watrous ML; Zetzl SE
    Pharmacoeconomics; 1993 Aug; 4(2):92-103. PubMed ID: 10146971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The potential for administrative cost savings under a capitation reimbursement system for prescription drugs.
    Standridge CR; Capettini R; Myers GM; Rao NB
    Public Health; 1983 Jan; 97(1):46-58. PubMed ID: 6342020
    [No Abstract]   [Full Text] [Related]  

  • 7. Case study using descriptive analysis to estimate hidden costs in processing third party prescriptions.
    Herrier RN; Spencer JR; Davis CD
    J Am Pharm Assoc (Wash); 2000; 40(5):658-65. PubMed ID: 11029847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Profitability, third-party reimbursement, and access to community pharmacies.
    Carroll NV; Miederhoff PA; Waters LW
    Clin Ther; 1996; 18(4):703-15; discussion 702. PubMed ID: 8879898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reimbursement and cost containment: a German perspective.
    Breyer F
    Pharmacoeconomics; 2002; 20 Suppl 3():87-94. PubMed ID: 12457429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimating pharmacy level prescription drug acquisition costs for third-party reimbursement.
    Kreling DH; Kirk KW
    Med Care; 1986 Jul; 24(7):590-600. PubMed ID: 3523065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prescribing outside the limits of marketing authorizations and reimbursement by the French universal health insurance system.
    Avouac B
    Joint Bone Spine; 2002 Dec; 69(6):534-7. PubMed ID: 12537259
    [No Abstract]   [Full Text] [Related]  

  • 12. Third party payment policies: design & impact.
    Schondelmeyer SW
    Am Pharm; 1986 Aug; NS26(8):41-5, 48-56, 63-8. PubMed ID: 3776831
    [No Abstract]   [Full Text] [Related]  

  • 13. [Prescription drugs and the aged: cost-free and cost-containment measures].
    Tremblay J
    Union Med Can; 1980 Mar; 109(3):414-20. PubMed ID: 7376292
    [No Abstract]   [Full Text] [Related]  

  • 14. Factors influencing pharmacists' participation in third-party programmes.
    Szeinbach SL
    J Clin Pharm Ther; 1990 Aug; 15(4):241-5. PubMed ID: 2229204
    [No Abstract]   [Full Text] [Related]  

  • 15. Reform of prescription drug reimbursement and pricing in the German social health insurance market: a comparison of three scenarios.
    Gress S; Niebuhr D; May U; Wasem J
    Pharmacoeconomics; 2007; 25(6):443-54. PubMed ID: 17523750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Do drug copayments work?
    David J
    CMAJ; 1994 May; 150(9):1491-3. PubMed ID: 8168015
    [No Abstract]   [Full Text] [Related]  

  • 17. Evaluating the impact of reference-based pricing.
    Grootendorst P; Holbrook A
    CMAJ; 1999 Aug; 161(3):273-4. PubMed ID: 10463048
    [No Abstract]   [Full Text] [Related]  

  • 18. Rising drug costs: the impact on dermatology.
    Rico MJ
    Skin Therapy Lett; 2000; 5(4):1-2,5. PubMed ID: 10785406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contraindications of nonprofit hospitals.
    Johnson S
    Mich Health Hosp; 1999; 35(4):78. PubMed ID: 10539278
    [No Abstract]   [Full Text] [Related]  

  • 20. The association of insurance type with costs of dispensed drugs.
    Mott DA; Kreling DH
    Inquiry; 1998; 35(1):23-35. PubMed ID: 9597015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.